AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2313000 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exercise group (Group A, n = 80)
Number of subjects: 184
Study 2313000 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exercise group (Group B, n = 42)
Number of subjects: 184
Study 2313000 — intervention group
Group type: COMPARATOR
Intervention: Contract control group (Group C, n = 62)
Number of subjects: 184
Study 7352857 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microL of 0.5% pilocarpine hydrochloride
Number of subjects: 10
Study 7352857 — intervention group
Group type: COMPARATOR
Intervention: 50 microL of 0.5% pilocarpine hydrochloride
Number of subjects: 10
Study 31840162 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole apple (WA) consumption
Number of subjects: 40
Study 31840162 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (CB)
Number of subjects: 40
Study 29789393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 65
Study 29789393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: Unflavoured e-liquid (UF2.0%)
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavoured e-liquid (FL2.0%)
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalator (Nicorette(®); 15 mg)
Number of subjects: 0
Study 26696273 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarette (CC; JPS Silver King Size, 0.6 mg)
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP with 0% nicotine
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP with 0.4% nicotine
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP with 0.9% nicotine
Number of subjects: 0
Study 26696273 — intervention group
Group type: EXPERIMENTAL
Intervention: EVP with 2.0% nicotine
Number of subjects: 0
Study 25317990 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric field-induced release and measurement (EFIRM) for saliva-based EGFR mutation detection
Number of subjects: 62
Study 22228146 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized screening with annual PSA testing for 6 years and annual DRE for 4 years (intervention arm)
Number of subjects: 76885
Study 22228146 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 76885
Study 22228146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control arms
Number of subjects: 76885
Study 20938948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packs with airways
Number of subjects: 39
Study 20938948 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally occluding nasal packs
Number of subjects: 39
Study 20938948 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Nasal packs with airways and Totally occluding nasal packs)
Number of subjects: 39
Study 18557715 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline 0.5-3.0 mg/h and albumin (group A)
Number of subjects: 40
Study 18557715 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 0.5-2 mg, 6 hourly and albumin (group B)
Number of subjects: 40
Study 16075193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) - home visitation by registered nurses pre‐ and postnatally
Number of subjects: 324
Study 16075193 — intervention group
Group type: COMPARATOR
Intervention: No visitation (Control)
Number of subjects: 324
Study 11934087 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assessment techniques
Number of subjects: 255
Study 11934087 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based with interruption (Web-I)
Number of subjects: 255
Study 11934087 — intervention group
Group type: COMPARATOR
Intervention: Paper-based (P&P)
Number of subjects: 255
Study 10462251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing three recombinant malaria antigens (MSP1 190LCS.T3, MSP2, RESA) with Montanide ISA720 adjuvant
Number of subjects: 0
Study 10462251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of antigens
Number of subjects: 0
Study 10462251 — intervention group
Group type: COMPARATOR
Intervention: MSP2 with Montanide ISA720
Number of subjects: 0
Study 10462251 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of antigens
Number of subjects: 0
Study 9050705 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with 2% mepivacaine
Number of subjects: 42
Study 9050705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 42
Study 1860020 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg fluphenazine decanoate every two weeks
Number of subjects: 0
Study 1860020 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate every two weeks
Number of subjects: 0
Study 1860020 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg fluphenazine decanoate
Number of subjects: 0
Study 1860020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine plasma levels
Number of subjects: 0
Study 6352119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol once daily (160-480 mg)
Number of subjects: 175
Study 6352119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol twice daily (160-480 mg)
Number of subjects: 175
Study 6352119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol once daily
Number of subjects: 175
Study 6352119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol twice daily
Number of subjects: 175
Study 31021358 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA)-based multi-ingredient nutritional supplement
Number of subjects: 38
Study 31021358 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 38
Study 30235653 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (specifics not provided)
Number of subjects: 371
Study 26774907 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) regimen
Number of subjects: 820
Study 24571588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IHC parameters
Number of subjects: 14
Study 24571588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PET/IHC characteristics
Number of subjects: 14
Study 21920481 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 125
Study 21920481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 20548096 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP therapy (rituximab plus CHOP)
Number of subjects: 399
Study 20548096 — intervention group
Group type: COMPARATOR
Intervention: CHOP therapy (standard CHOP chemotherapy)
Number of subjects: 399
Study 20548096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both R-CHOP and CHOP
Number of subjects: 399
Study 17604557 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 135
Study 17604557 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (using the Streitberger placebo needle)
Number of subjects: 135
Study 16083541 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 1124
Study 16083541 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 1124
Study 12372444 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b
Number of subjects: 52
Study 12372444 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 52
Study 12372444 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogs depot
Number of subjects: 52
Study 12372444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 52
Study 9923794 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 30
Study 9923794 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN plus daily injections of GH
Number of subjects: 30
Study 9923794 — intervention group
Group type: EXPERIMENTAL
Intervention: GH and insulin combined with TPN
Number of subjects: 30
Study 9923794 — intervention group
Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 30
Study 9923794 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 30
Study 9923794 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 30
Study 7586108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (120 micrograms.kg‐1)
Number of subjects: 27
Study 7586108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium (150 micrograms.kg‐1)
Number of subjects: 27
Study 7586108 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 27
Study 7586108 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium
Number of subjects: 27
Study 1540100 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving
Number of subjects: 284
Study 1540100 — intervention group
Group type: COMPARATOR
Intervention: Single glove
Number of subjects: 284
Study 3929312 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5 - 8.0 mg/day)
Number of subjects: 7
Study 3929312 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg/day)
Number of subjects: 7
Study 3929312 — intervention group
Group type: COMPARATOR
Intervention: Placebo buprenorphine
Number of subjects: 7
Study 3929312 — intervention group
Group type: COMPARATOR
Intervention: Placebo buprenorphine plus heroin self-administration
Number of subjects: 7
Study 3929312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (buprenorphine and placebo plus heroin)
Number of subjects: 7
Study 29607525 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC remission at end-of-treatment
Number of subjects: 103
Study 26733703 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed premium adjustment ($550 incentive)
Number of subjects: 197
Study 26733703 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate premium adjustment ($550 incentive)
Number of subjects: 197
Study 26733703 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily lottery incentive ($550 incentive)
Number of subjects: 197
Study 26733703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no financial incentive)
Number of subjects: 197
Study 25851298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 μg
Number of subjects: 301
Study 25851298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 2.5 μg
Number of subjects: 301
Study 25851298 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 1.25 μg
Number of subjects: 301
Study 25851298 — intervention group
Group type: COMPARATOR
Intervention: Placebo Respimat®
Number of subjects: 301
Study 23796683 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based strategy training (adapted version of CO-OP), provided in two 1-hour sessions per week for 10 weeks
Number of subjects: 13
Study 21664605 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12
Study 21664605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17509694 — intervention group
Group type: EXPERIMENTAL
Intervention: Contactus program (educational program with six lectures and group discussions)
Number of subjects: 319
Study 17509694 — intervention group
Group type: EXPERIMENTAL
Intervention: Contactus program
Number of subjects: 319
Study 16415901 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 212
Study 16415901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 12827578 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with antioxidants (vitamin E, vitamin C, allopurinol, and acetylcysteine)
Number of subjects: 22
Study 12827578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study 10857897 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intensification (HDCVP): six courses of FAC followed by two courses of cyclophosphamide (5.25 g/m2), etoposide (1,500 mg/m2), and cisplatin (165 mg/m2)
Number of subjects: 46
Study 10857897 — intervention group
Group type: COMPARATOR
Intervention: Standard dose chemotherapy (FAC): 5-fluorouracil, doxorubicin, and cyclophosphamide every 3 weeks for nine courses (control)
Number of subjects: 46
Study 9766154 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects with macrovascular complications
Number of subjects: 69
Study 9766154 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects without macrovascular complications
Number of subjects: 69
Study 9766154 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 7940345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclonate P (sodium diclofenac)
Number of subjects: 74
Study 3207540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 90
Study 3207540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 90
Study 3207540 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated Hypertensive Patients
Number of subjects: 90
Study 29355435 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR342434 (SAR-Lis)
Number of subjects: 1012
Study 29355435 — intervention group
Group type: COMPARATOR
Intervention: Ly-Lis (Humalog)
Number of subjects: 1012
Study 27355239 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐TTRRx (ISIS 420915), a 2nd‐Generation 2'‐O‐(2‐methoxyethyl) modified antisense oligonucleotide (ASO) targeting TTR RNA transcript, administered for four weeks.
Number of subjects: 0
Study 27355239 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐TTRRx (ISIS 420915)
Number of subjects: 0
Study 24796766 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (25 mg three times a day)
Number of subjects: 32
Study 24796766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23174579 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 189
Study 23174579 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study 20236550 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (VT of 10 to 12 ml/kg predicted body weight)
Number of subjects: 20
Study 20236550 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume (VT of 5 to 7 ml/kg predicted body weight)
Number of subjects: 20
Study 18608197 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg losartan (ARB)
Number of subjects: 21
Study 18608197 — intervention group
Group type: COMPARATOR
Intervention: 5 mg amlodipine (CCB)
Number of subjects: 21
Study 15719902 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative skin antiseptics
Number of subjects: 0
Study 11790231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transorbital approach using transcranial Doppler
Number of subjects: 57
Study 11790231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (all approaches)
Number of subjects: 57
Study 11790231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (transorbital approach)
Number of subjects: 57
Study 7486244 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH)
Number of subjects: 28
Study 7486244 — intervention group
Group type: COMPARATOR
Intervention: Control group (age/gender-matched controls of normal stature)
Number of subjects: 28
Study 2686427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 300 mg IV
Number of subjects: 106
Study 2686427 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1000 mg IV
Number of subjects: 106
Study 7223 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 28
Study 7223 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam
Number of subjects: 28
Study 7223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 7223 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam and lorazepam
Number of subjects: 28
Study 31000133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Number of subjects: 125
Study 31000133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg) every 4 hours when body temperature exceeded 38°C during hospitalisation
Number of subjects: 125
Study 31000133 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (500 mg)
Number of subjects: 125
Study 31000133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 125
Study 28503826 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended chemoradiotherapy (XCRT) - three cycles of fluorouracil based chemotherapy during a 10 week wait period
Number of subjects: 49
Study 28503826 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (SCRT) - standard 10 week wait period before surgery
Number of subjects: 49
Study 25910950 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and temozolomide with vandetanib (100 mg daily)
Number of subjects: 106
Study 25910950 — intervention group
Group type: COMPARATOR
Intervention: RT and temozolomide without vandetanib
Number of subjects: 106
Study 23422380 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (DLX) 60 mg once daily for 11 days
Number of subjects: 26
Study 23422380 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (ESC) 20 mg once daily for 11 days
Number of subjects: 26
Study 21046164 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 37
Study 21046164 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 37
Study 19296284 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated early intervention programme led by school staff
Number of subjects: 260
Study 19296284 — intervention group
Group type: COMPARATOR
Intervention: Monitoring condition
Number of subjects: 260
Study 17545499 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively worded living will
Number of subjects: 233
Study 17545499 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively worded living will
Number of subjects: 233
Study 17545499 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-choice format living will
Number of subjects: 233
Study 17545499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample living will representing the default preference
Number of subjects: 233
Study 14975456 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiproliferative drug‐eluting stents (DES)
Number of subjects: 0
Study 14975456 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting (bare metal stents)
Number of subjects: 0
Study 11452321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered in the buttock (n = 123)
Number of subjects: 258
Study 11452321 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine administered in the anterolateral thigh muscle (n = 135)
Number of subjects: 258
Study 9610531 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/h transdermal nitroglycerin (NTG) patches
Number of subjects: 291
Study 9610531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 7933697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus)
Number of subjects: 60
Study 7933697 — intervention group
Group type: COMPARATOR
Intervention: BSS Plus
Number of subjects: 60
Study 7933697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal hemocoagulase
Number of subjects: 60
Study 3074462 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg b.i.d. for lower UTI; 400 mg b.i.d. for upper UTI
Number of subjects: 172
Study 3074462 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) b.i.d. for seven days
Number of subjects: 172
Study 412580 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant topical mechlorethamine after electron beam therapy
Number of subjects: 100
Study 412580 — intervention group
Group type: COMPARATOR
Intervention: Electron beam therapy alone
Number of subjects: 100
Study 31025260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 108 CFU g−1 Lactobacillus bulgaricus
Number of subjects: 240
Study 31025260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing encapsulated Lactobacillus bulgaricus
Number of subjects: 240
Study 31025260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet without Lactobacillus bulgaricus
Number of subjects: 240
Study 31025260 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet for 45 days, then exposed to Pb)
Number of subjects: 240
Study 30903342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (15 mg/kg IV TXA given on induction, additional doses at 3 hours and 6 hours post-incision)
Number of subjects: 180
Study 30903342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (15 mg/kg IV TXA given on induction, additional dose at 3 hours post-incision)
Number of subjects: 180
Study 30903342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (15 mg/kg IV TXA given on induction)
Number of subjects: 180
Study 28813433 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD without exacerbations
Number of subjects: 18684
Study 28813433 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD with exacerbations
Number of subjects: 18684
Study 28813433 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD exacerbations post-diabetes
Number of subjects: 18684
Study 28813433 — intervention group
Group type: COMPARATOR
Intervention: No COPD
Number of subjects: 18684
Study 25573400 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg/d), vitamin B6 (50 mg/d), and vitamin B12 (1 mg/d)
Number of subjects: 4331
Study 25573400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4331
Study 23926425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) support during treadmill walking
Number of subjects: 22
Study 23926425 — intervention group
Group type: COMPARATOR
Intervention: Full weight bearing during treadmill walking
Number of subjects: 22
Study 22777119 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Enteral Nutrition (EN)
Number of subjects: 10